GlassScriptPhysician profile
Timothy J Campbell
NPI 1891923074
$18,408.11
in general payments reported to CMS, 2019-2025
42 companies · $3,978 in 2025
The $3,978 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,416 · 2020: $2,431 · 2021: $2,179 · 2022: $2,450 · 2023: $2,340 · 2024: $2,613 · 2025: $3,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,844 · Consulting Fee: $47.19 · Education: $40.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,843.65 |
| Consulting Fee | $47.19 |
| Education | $40.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,974.82 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $1,964.63 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Optinose US, INC. | $1,500.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,437.58 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,199.56 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,140.92 | 2019-2025 | |
| Pfizer INC. | $1,074.74 | 2019-2025 | |
| Grifols USA, LLC | $853.57 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $844.51 | 2020-2025 | Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $724.21 | 2021-2025 | Orladeyo, Orladeyo |
| Genentech USA, INC. | $569.85 | 2019-2025 | Xolair |
| Kaleo, INC. | $542.99 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $430.31 | 2023-2025 | Ayvakit |
| Pharming Healthcare, INC. | $396.44 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $356.91 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.